

# Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Jessie Yanxiang Guo,<sup>1,2,3,8</sup> Hsin-Yi Chen,<sup>1,2,8</sup> Robin Mathew,<sup>1,4,8</sup> Jing Fan,<sup>5,8</sup> Anne M. Strohecker,<sup>1,4</sup> Gizem Karsli-Uzunbas,<sup>1,2</sup> Jurre J. Kamphorst,<sup>5</sup> Guanghua Chen,<sup>1,2</sup> Johanna M.S. Lemons,<sup>5</sup> Vassiliki Karantza,<sup>1,6</sup> Hilary A. Collier,<sup>1,7</sup> Robert S. DiPaola,<sup>1,6</sup> Celine Gelinas,<sup>1,3,4</sup> Joshua D. Rabinowitz,<sup>1,5</sup> and Eileen White<sup>1,2,4,9</sup>

<sup>1</sup>The Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA; <sup>2</sup>Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, New Jersey 08854, USA; <sup>3</sup>Department of Biochemistry, Center for Advanced Biotechnology and Medicine, Piscataway, New Jersey 08854, USA; <sup>4</sup>University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA; <sup>5</sup>Department of Chemistry, Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey 08544, USA; <sup>6</sup>Division of Medical Oncology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Jersey 08854, USA; <sup>7</sup>Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544, USA

**Autophagy is a catabolic pathway used by cells to support metabolism in response to starvation and to clear damaged proteins and organelles in response to stress. We report here that expression of a *H-ras*<sup>V12</sup> or *K-ras*<sup>V12</sup> oncogene up-regulates basal autophagy, which is required for tumor cell survival in starvation and in tumorigenesis. In Ras-expressing cells, defective autophagosome formation or cargo delivery causes accumulation of abnormal mitochondria and reduced oxygen consumption. Autophagy defects also lead to tricarboxylic acid (TCA) cycle metabolite and energy depletion in starvation. As mitochondria sustain viability of Ras-expressing cells in starvation, autophagy is required to maintain the pool of functional mitochondria necessary to support growth of Ras-driven tumors. Human cancer cell lines bearing activating mutations in Ras commonly have high levels of basal autophagy, and, in a subset of these, down-regulating the expression of essential autophagy proteins impaired cell growth. As cancers with Ras mutations have a poor prognosis, this “autophagy addiction” suggests that targeting autophagy and mitochondrial metabolism are valuable new approaches to treat these aggressive cancers.**

[*Keywords:* autophagy; p62; Ras; cancer; metabolism; mitochondria]

Supplemental material is available for this article.

Received November 25, 2010; revised version accepted January 18, 2011.

The products of essential autophagy genes (*atg*)—*atg5*, *atg6/beclin1*, *atg7*, and *lc3/atg8*, among others—respond to starvation, forming double-membrane phagophores that engulf cellular proteins, lipids, and organelles, capturing them in autophagosomes that are degraded in lysosomes (Levine and Kroemer 2008). This catabolic cellular self-degradation provides a mechanism to produce building blocks for macromolecular synthesis and maintain energy homeostasis through intracellular recycling in periods of nutrient limitation (Rabinowitz and White 2010). In established tumors, autophagy is up-regulated in hypoxic tumor regions where it promotes survival, indicating that cancer cells use the catabolic function of autophagy to tolerate stress (Degenhardt et al. 2006; Mathew et al.

2007a,b, 2009). As autophagy primarily generates substrates for oxidative metabolism, the means by which autophagy promotes survival in hypoxia are not clear.

Autophagy also mitigates cellular damage by preventing the toxic buildup of unfolded and aggregation-prone proteins, lipids, and damaged organelles. This waste removal function of autophagy may be important for both cell survival and tumor suppression (Mathew et al. 2007a; Levine and Kroemer 2008; White et al. 2010). Autophagy defects cause accumulation of p62 and ubiquitin (Ub)-containing protein aggregates and damaged organelles, particularly mitochondria (Hara et al. 2006; Komatsu et al. 2006, 2007; Mathew et al. 2009). This is associated with production of reactive oxygen species (ROS), genome damage, and spontaneous tumor development, suggesting that autophagy suppresses chronic tissue damage and cancer initiation (Mathew et al. 2009). Since autophagy both mitigates damage and maintains energy homeostasis, we hypothesized that autophagy has opposing roles in cancer

<sup>8</sup>These authors contributed equally to this work.

<sup>9</sup>Corresponding author.

E-MAIL whiteei@umdnj.edu; FAX (732) 235-5795.

Article published online ahead of print. Article and publication date are online at <http://www.genesdev.org/cgi/doi/10.1101/gad.2016311>.

initiation and in established tumors. Whereas damage mitigation may be important for suppressing tumor initiation, in aggressive cancers, growth in a stressed micro-environment may instead cause dependency on autophagy for survival. We envisioned that the tumor-promoting role of autophagy is twofold: providing energy substrates during periods of nutrient limitation, and preserving organelle function required for cell growth. To test this hypothesis, we examined the levels of autophagy in models of aggressive cancers, focusing on those with activating mutations in H-ras and K-ras. Indeed, introduction of activated Ras promoted tumorigenesis but also up-regulated basal autophagy that was required for maintenance of mitochondrial metabolism, cell growth, and cellular viability in vitro and in vivo in tumors. Since human cancer cell lines with active Ras can similarly depend on autophagy, this suggests that targeting tumor cell metabolism by autophagy inhibition may be a valuable approach to therapy for aggressive cancers with Ras mutations.


## Results

### Activated Ras-expressing cells are dependent on autophagy to survive starvation

We tested the hypothesis that activation of a strong cell growth-promoting oncogene such as *H-ras*<sup>V12</sup> or *K-ras*<sup>V12</sup>

would alter the requirement for autophagy. Specifically, we hypothesized that cells expressing activated Ras would be less able to reduce metabolic expenditure during starvation; accordingly, they might be more dependent on autophagy. *H-ras*<sup>V12</sup> or *K-ras*<sup>V12</sup> genes were introduced into immortal, nontumorigenic baby mouse kidney epithelial (iBMK) cells (Supplemental Figs. S1A, S2A). The level of Ras expression in iBMK cell lines was comparable with that in human cancer cell lines with activating Ras mutations (see below).

Autophagy was measured by the frequency of cells displaying membrane translocation of the autophagosome component reporter LC3, and by assessing proteolytic processing of endogenous LC3-I to LC3-II. In iBMK cell lines without Ras, the level of basal autophagy was low (0%–5%) in nutrient-replete conditions and was up-regulated >10-fold by starvation (Hank's balanced salt solution [HBSS]) (Fig. 1A,B; Supplemental Figs. S1D, S2B,C). In contrast, expression of *H-ras*<sup>V12</sup> or *K-ras*<sup>V12</sup> (Ras) increased basal autophagy 10-fold and limited starvation-induced autophagy (Fig. 1A,B; Supplemental Figs. S1B,D, 2B,C). Isogenic iBMK cell lines deficient for the essential autophagy genes *atg5* or *atg7* were completely defective for autophagy (Fig. 1A,B, Supplemental Figs. S1D, S2B,C), and allelic loss of the essential autophagy gene *beclin1* produced a partial autophagy defect (Supplemental Fig.



**Figure 1.** *H-ras*<sup>V12</sup>-expressing cells are dependent on autophagy to survive starvation. (A) Autophagy-competent (*atg5*<sup>+/+</sup> and *atg7*<sup>+/+</sup>) or autophagy-deficient (*atg5*<sup>-/-</sup> and *atg7*<sup>-/-</sup>) cells expressing *H-ras*<sup>V12</sup> or vector were transiently transfected with the fluorescent autophagosome marker p-tFL-LC3 and subjected to starvation. Representative images depict RFP-LC3 localization. Numbers indicate percentage of cells with LC3 translocation to autophagosomes (punctate localization). (B) Evaluation for processing of endogenous LC3-I to LC3-II indicative of autophagy induction and activation of caspase-3 (apoptosis). (C) Ras-expressing cells were treated with HBSS for 12–20 h, and cell viability was examined by a trypan blue exclusion-based cell viability analyzer and normalized to untreated cells at the time of initiation of starvation. (D) Cells treated as in C were allowed to recover in normal medium for 2 d and assessed for clonogenic survival.


S1B,C). Accumulation of the autophagy substrate p62 was observed only when autophagy was genetically impaired in vitro (Supplemental Figs. S1A, S2A) or in vivo (see below), suggesting that overexpression of Ras does not interfere with autophagic flux. This high level of autophagy in Ras-expressing cells occurred despite active mTOR, which suppresses autophagy and is activated by Ras, as levels of phospho-S6 were comparable between Ras-expressing cells and control cells (Supplemental Fig. S1E). This suggests that the high basal autophagy caused by Ras is not due to down-regulation of mTOR and must result from an mTOR-independent mechanism.

In nutrient-replete conditions, autophagy deficiency had no effect on proliferation or survival of Ras-expressing cells (Fig. 1C,D; Supplemental Fig. S2C,E). In starvation, Ras-expressing, autophagy-competent cells survived, whereas autophagy-deficient cells did not, and loss of viability was accompanied by activation of caspase-3 (Fig. 1B; Supplemental Fig. S2D). Starvation sensitivity of autophagy-deficient cells was Ras-dependent, since autophagy status did not dramatically affect survival of cells without Ras (Fig. 1C,D; Supplemental Fig. S1F). Survival impairment in starvation correlated with the severity of the autophagy defect, as Ras-expressing *atg5*<sup>-/-</sup> and *atg7*<sup>-/-</sup> cells were more sensitive to starvation (Fig. 1C,D; Supplemen-

tal Figs. S1F, S2D,E) than those with allelic loss of *beclin1* (Supplemental Fig. S1G,H). Autophagy defects similarly sensitized to cell death in ischemia (glucose deprivation and 1% oxygen) (data not shown) but not to the proapoptotic ATP-competitive nonselective kinase inhibitor staurosporine (Supplemental Fig. S1I), suggesting that autophagy-dependent survival was specific to metabolic stress. Apoptosis of Ras-expressing, autophagy-defective cells was not rescued by methyl-pyruvate (Supplemental Fig. S1J) or ROS scavengers (Supplemental Fig. S1K), nor was ROS production apparent (Supplemental Fig. S1L), suggesting that survival impairment was not due to mitochondrial substrate limitation or elevated oxidative stress. Autophagy defects did not alter the level of GTP-bound Ras (Supplemental Fig. S1M), indicating that autophagy promotes survival independently of Ras activity. Thus, Ras expression promotes cellular survival in an autophagy-dependent manner when nutrients are limiting.

#### Autophagy supports activated Ras-mediated tumorigenesis

To assess the role of autophagy in Ras-mediated tumorigenesis, nontumorigenic iBMK cells transduced with Ras, which dramatically promotes tumor formation (Fig. 2A,D;



**Figure 2.** Autophagy supports Ras tumorigenesis. (A) Tumor growth of Ras-expressing *atg5*<sup>+/+</sup> and *atg5*<sup>-/-</sup> cells. Error bars represent standard errors. (\*)  $P < 0.05$ ; (\*\*)  $P < 0.01$  (*t*-test). (B) Representative tumor-bearing mice at day 13 (51 and 10) or day 15 (49 and 24) post-injection from A. (C) Histology (H&E) and immunohistochemistry for active caspase-3, p62, or Ub in tumors from A. (D–F) Ras-expressing *atg7*<sup>-/-</sup> tumors show reduced growth, elevated apoptosis, and accumulation of p62 and Ub. Error bars represent standard errors. (\*)  $P < 0.05$ ; (\*\*)  $P < 0.01$  (*t*-test).



Supplemental Fig. S2F; Degenhardt et al. 2006), were grown in nude mice. Ras-expressing  $atg5^{-/-}$  and  $atg7^{-/-}$  cells displayed reduced tumor growth (Fig. 2 A,B,D,E; Supplemental Fig. S2F,G) and tumors displayed abnormal histology, active caspase-3, and p62 and Ub accumulation (Fig. 2C,F; Supplemental Fig. S2H). The defect in tumorigenesis was more pronounced in  $atg5^{-/-}$  and  $atg7^{-/-}$  cells than those with  $beclin1^{+/-}$ , which caused impaired tumor growth only in the context of high Ras expression [ $beclin1^{+/-}$  Hras2-15 and  $beclin1^{+/-}$ -Hras2) (Supplemental Fig. S3 A-C). Thus, a complete autophagy defect was more effective at compromising tumorigenesis by Ras. Facilitation of tumorigenesis by autophagy is Ras-specific, since growth of tumors without Ras is not reduced by autophagy deficiency (Degenhardt et al. 2006; Mathew et al. 2007b, 2009). Autophagy-competent and autophagy-defective Ras-expressing tumors stably expressing the autophagy reporter LC3 showed punctate LC3 distribution indicative of autophagosome formation in an  $atg5$ -dependent manner (Supplemental Fig. S3D), demonstrating that autophagy was active in Ras-driven tumors.


#### p62 is required for efficient tumorigenesis by Ras

The autophagy cargo receptor p62 binds LC3 and Ub on modified proteins, including those on organelles such as depolarized mitochondria, thereby targeting cargo to autophagosomes for degradation (Pankiv et al. 2007; Geisler et al. 2010). Interestingly, deficiency in p62 impairs spontaneous lung adenocarcinoma development in mice upon activation of an oncogenic *K-ras* allele (Duran et al. 2008). We tested the hypothesis that p62 deficiency impairs cargo delivery to autophagosomes, thereby compromising Ras tumorigenesis by the same mechanism as deficiency in


$atg5$  or  $atg7$ . Ras-expressing  $p62^{-/-}$  iBMK cells (Fig. 3A) had reduced viability in starvation (Fig. 3B,C; Supplemental Fig. S4A) and decreased tumorigenicity in comparison with  $p62^{+/+}$  and p62-reconstituted controls (Fig. 3D,E,G,H). Ras-expressing  $p62^{-/-}$  tumors showed abnormal histology, apoptosis (active caspase-3), and Ub accumulation (Fig. 3F,I), indistinguishable from Ras-expressing  $atg5^{-/-}$  and  $atg7^{-/-}$  tumors. Thus, interfering with either autophagosome cargo delivery or autophagosome formation has the common feature of impeding Ras-dependent tumorigenesis.

#### High basal autophagy in human cancer cell lines with Ras mutations

To further confirm that autophagy plays a role in the growth and survival of human cancer cell lines with activating mutations in Ras, we evaluated the consequence of autophagy inhibition. We assessed the requirement of autophagy for growth and survival in T24 (bladder carcinoma cell line, H-ras<sup>G12V</sup> mutation), H1299 (lung carcinoma cell line, N-ras<sup>G12C</sup> mutation), H460 (large-cell lung cancer cell line, K-ras<sup>Q61H</sup> mutation), PANC-1 (pancreatic adenocarcinoma cell line, K-ras<sup>G12V</sup> mutation), HCT-116 (colorectal carcinoma cell line, K-ras<sup>G13D</sup> mutation), and PC-3 (prostate carcinoma cell line, wild-type Ras). The level of activated Ras expression in the human cancer cell lines was comparable with the iBMK cell lines where activated Ras expression was engineered (Fig. 4A). Except for PC3, the human cancer cell lines have high phospho-ERK (Fig. 4A), consistent with high flux through the Ras pathway. Autophagy was assessed in two ways: by the frequency of cells displaying membrane translocation of the autophagosome marker tandem-tagged p-TFL-LC3 via



**Figure 3.** p62 is required for efficient tumorigenesis by Ras. (A) HA-tagged H-ras<sup>V12</sup> was stably expressed in  $p62^{+/+}$  and  $p62^{-/-}$  iBMK cells in which p62 expression was reconstituted. Western blot shows the protein level of HA-Hras<sup>V12</sup>, Flag-HA-p62, EGFP-p62, and endogenous p62. (B,C)  $p62^{-/-}$ -Hras<sup>V12</sup> cells expressing vector or p62 were treated with HBSS for 16 h and then analyzed for viability (B) and clonogenic survival (C) as described in Figure 1, C and D. (D) Tumorigenesis of Ras-expressing,  $p62^{+/+}$ , or  $p62^{-/-}$  iBMK cells. Error bars represent standard errors. (\*)  $P < 0.05$ ; (\*\*)  $P < 0.01$  (*t*-test). (E) Mice at day 16 post-injection from D. (F) H&E and immunohistochemistry for activated caspase-3 and Ub in tumors from D. (G) Tumor growth of  $p62^{-/-}$ -Hras<sup>V12</sup> iBMK cells expressing EGFP or EGFP-p62. Error bars represent standard errors. (\*)  $P < 0.05$ ; (\*\*)  $P < 0.01$  (*t*-test). (H) Mice from G at day 15 post-injection. (I) H&E and immunohistochemistry of tumors from G.



**Figure 4.** Sensitivity of human cancer cell lines with activating Ras mutations to autophagy inhibition. (A, top panel) Western blot shows the protein level of HA-K-ras<sup>V12</sup> in an iBMK cell line, endogenous Ras, phospho-p42/44, and p42/44 in human cancer cell lines. The bottom graph shows quantification of Ras levels relative to  $\beta$ -actin. (B) Human cancer cells were transiently transfected with the fluorescent autophagosome marker p-tFL-LC3 and cultured in nutrient-replete conditions. Representative images depict RFP-LC3 localization. Numbers indicate percentage of cells with LC3 translocation to autophagosomes (punctate localization). (C, top panel) Human cancer cells were cultured under nutrient-replete conditions and collected at 30% of confluence to evaluate processing of endogenous LC3-I to LC3-II. (Bottom panel) The ratio of LC3-II to LC3-I expression is shown quantitatively as a graph. (D) Evaluation of processing of endogenous LC3-I to LC3-II of human cancer cell lines under CQ (30  $\mu$ M) treatment to block flux through the autophagy pathway. Human cancer cells were cultured under nutrient-replete conditions, treated with CQ when cells were 25%–30% confluent, and assessed in comparison with cells at the start of CQ administration. (E) Growth curve of six different cancer cell lines treated with 30  $\mu$ M CQ from D. (F, top panel) Western blot shows expression of Atg5 and Atg7. (Bottom panel) Cell viability of six different cancer cell lines in response to lentiviral shRNA knockdown of essential autophagy regulators Atg5 and Atg7.

immunofluorescence, and by examining proteolytic processing of endogenous LC3-I to LC3-II (Fig. 4B,C). In nutrient-replete conditions, basal autophagy was up-regulated in the human cancer cells, with the exception of H460. Where H460 had few LC3 puncta and predominant LC3-I, the other human cancer cell lines had a severalfold increase in LC3 puncta and predominant LC3-II, indicative of high basal autophagy (Fig. 4B,C).

Autophagosome accumulation can be due to induction of autophagy or inhibition of flux through the autophagy pathway. To assess flux, the autophagy substrates LC3 and p62 were monitored in the presence of chloroquine (CQ), which blocks lysosome acidification, degradation of autophagosome contents, and flux through the pathway. All cell lines accumulated LC3-II and p62 in the presence of CQ, indicative of high autophagic flux, although H460 did

so with slower kinetics, as expected (Fig. 4D). Thus, the high level of autophagosome formation in human cancer cell lines is due to high basal autophagy.

#### *Autophagy facilitates growth and survival of human cancer cell lines with active Ras*

To test if high basal autophagy was required for growth or survival in human cancer cell lines with activated Ras, viability was monitored in the presence of autophagy inhibitor CQ. Among cell lines with high basal autophagy, CQ dramatically suppressed growth of T24, and attenuated growth of H1299, PC-3, PANC-1, and HCT116 (Fig. 4E). In contrast, CQ did not affect proliferation of H460, which has low basal autophagy (Fig. 4E).

To further probe the significance of autophagy in human cancer cell lines with Ras mutations, the functional consequence of lentiviral knockdown of essential autophagy regulators Atg5 and Atg7 was assessed. Atg5 and Atg7 expression was suppressed by targeted shRNAs, and this was associated with a dramatic decrease in cell survival of the T24, H1299, and HCT116 cell lines (which were also sensitive to CQ) but not the others (Fig. 4F). Taken together, our results demonstrate that a subset of human cancer cell lines with activating mutations in Ras rely on autophagy for normal growth and survival.

#### *Autophagy supports cancer cell survival through the maintenance of mitochondrial metabolic function and energy levels*


To begin to address the mechanism by which autophagy defects impair survival and tumorigenesis when Ras is activated, isogenic iBMK tumors that were either wild-type or defective for autophagy were examined by electron microscopy. In Ras-expressing *atg5*<sup>-/-</sup>, *atg7*<sup>-/-</sup>, *beclin1*<sup>+/-</sup>, and *p62*<sup>-/-</sup> tumors, there was striking accumulation of abnormal, swollen mitochondria consistent with defective mitophagy (Fig. 5A; Supplemental Fig. S5A). Mitophagy is triggered by mitochondrial depolarization, translocation of the E3 ligase Parkin to mitochondria, and ubiquitination of mitochondrial proteins, causing p62 binding and autophagosome targeting (Wild and Dikic 2010). To assess mitophagy initiation in starvation, Ras-expressing *atg5*<sup>+/+</sup> and *atg5*<sup>-/-</sup> cells were transfected with a tagged Parkin expression vector and examined pre- and post-starvation for mitochondrial translocation (Narendra et al. 2008). Parkin translocation occurred at low levels in Ras-expressing *atg5*<sup>+/+</sup> and *atg5*<sup>-/-</sup> cells under nutrient-replete conditions, and was induced by either the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) or starvation, independently of autophagy functional status (Supplemental Fig. S5B). *atg5* deficiency impaired clearance of Parkin following starvation, consistent with defective mitophagy (Fig. 5B). The failure of autophagy-defective cells to engage mitophagy-mediated degradation of mitochondria in starvation was also evident from the sustained high levels of the mitochondrial protein Tom20 (Fig. 5B; Supplemental Fig. S5C). To test if mitochondrial function was required for viability in starvation,

mitochondria were depolarized with CCCP and survival in starvation was assessed. While mitochondrial depolarization had no effect on cell survival in nutrient-replete conditions, viability in starvation was abrogated independently of autophagy status (Fig. 5C; Supplemental Fig. S6A). Thus, mitochondrial function is critical for cellular survival in starvation.

To test if autophagy defects impair mitochondrial function, maintenance of mitochondrial membrane potential was examined. When starved, autophagy-defective cells more readily lost membrane potential, and the severity of the effect correlated with the level of autophagy deficiency, consistent with reduced mitochondrial functionality (Supplemental Fig. S5D). To test if stress-induced accumulation of abnormal mitochondria impacted mitochondrial metabolism, relative pool sizes of tricarboxylic acid (TCA) cycle intermediates in Ras-expressing *atg5*<sup>+/+</sup> and *atg5*<sup>-/-</sup> cells were examined by LC-MS under nutrient-replete (pyruvate-free DMEM) and starvation (HBSS) conditions. All TCA metabolites showed appreciable basal levels in both *atg5*<sup>+/+</sup> and *atg5*<sup>-/-</sup> cells, which were dramatically reduced under starvation (Fig. 5D). Importantly, TCA metabolites that are exclusively produced in the mitochondria (citrate, aconitate, and isocitrate) showed reduced levels in Ras-expressing *atg5*<sup>-/-</sup> cells compared with *atg5*<sup>+/+</sup> cells under both basal and starvation conditions (Fig. 5D; data not shown), with citrate depleted to almost undetectable levels during starvation of *atg5*<sup>-/-</sup> Hras cells. This was not the case for TCA metabolites that can also be produced in the cytosol from amino acid carbon skeletons ( $\alpha$ -ketoglutarate from glutamine, and fumarate and malate from aspartate) (Fig. 5D). This citrate and isocitrate depletion was not observed in autophagy-deficient cells when tumorigenesis was rendered with an oncogene other than Ras (Bcl-2), suggesting Ras-specific effect (Supplemental Fig. S6B). Pyruvate, the final product of glycolysis, which can be taken up by mitochondria to produce acetyl-CoA and thus citrate, was actually slightly elevated in the *atg5*<sup>-/-</sup> cells. Thus, autophagy deficiency depletes mitochondrially produced TCA cycle metabolites, likely by impairing mitochondrial conversion of pyruvate and/or fatty acids into acetyl-CoA and citrate under Ras expression. As Ras is known to promote conversion of pyruvate to lactate and to suppress oxidation of fatty acids (Kim and Dang 2006), this may increase the requirement for autophagy to supply substrates for mitochondrial metabolism and preserve mitochondrial function.

To test if autophagy deficiency also resulted in impaired mitochondrial respiration, oxygen consumption (OCR) was examined without and with an uncoupler (p-trifluoromethoxy carbonyl cyanide phenyl hydrazone [FCCP]) to assess the spare respiratory capacity (SRC) (Choi et al. 2009), an indicator of the potential reserve capacity for bioenergetic function in cells (Dranka et al. 2010). Under nutrient-replete conditions, Ras-expressing autophagy-competent cells showed appreciable OCR, which was elevated by FCCP and pyruvate and reduced under starvation (Fig. 5E; Supplemental Fig. S6C). Thus, the autophagy-competent cells effectively tailored mitochondrial respiration to ATP needs and substrate availability. In





**Figure 5.** Autophagy maintains mitochondrial oxidative metabolism. (A) Representative EMs show the accumulation of dysmorphic mitochondria (arrows) of Ras-expressing, autophagy-defective tumors. *Insets* show typical mitochondrial morphology. (B) mCherry-Parkin-expressing cells were treated with HBSS for 7 h, then fixed and stained with the mitochondrial marker Tom20. Representative images show mitochondrial clearance in *atg5*<sup>+/+</sup> cells during starvation (reduction in Parkin- and Tom 20-positive cells). Numbers indicate percentage of Parkin-expressing cells. (C) Autophagy-competent or autophagy-deficient cells expressing Ras were pretreated with CCCP (20  $\mu$ M) for 4 h to induce mitochondrial uncoupling, and then subjected to HBSS + CCCP treatment for another 4 h. Cells were allowed to recover for 20 h and assessed for clonogenic survival. DMSO was used for CCCP control. (D) Pool sizes of major TCA cycle intermediates in *atg5*<sup>+/+</sup>-Hras and *atg5*<sup>-/-</sup>-Hras cells under nutrient-replete and starvation conditions. Graphs showing cell number normalized relative pool sizes (arbitrary unit [a.u.]) of major TCA metabolites by LC-MS in HBSS for the indicated times. (E) Oxygen consumption rates in cells under nutrient-replete conditions, following addition of FCCP (1.5  $\mu$ M) to establish maximum respiratory capacity and complex III inhibitor anti-mycin (20  $\mu$ M) to inhibit mitochondrial respiration. Measurements were done in DMEM without and with sodium pyruvate (0.11 g/L) (*top panels*) or in HBSS (*bottom panel*). (F) EC ([ATP] + [0.5ADP])/([ATP] + [ADP] + [AMP]) in *atg5*<sup>+/+</sup> and *atg5*<sup>-/-</sup> cells without or with Ras under nutrient-replete and starvation conditions.

contrast, Ras-expressing, autophagy-deficient cells showed reduced OCR levels and a blunted FCCP and pyruvate response, as well as a blunted response to starvation. Thus, distinct from any shortage of metabolic substrates, the Ras-expressing, autophagy-defective cells are fundamentally impaired in mitochondrial respiration (Fig. 5E; Supplemental S6C).

Given that autophagy deficiency in Ras-expressing tumor cells resulted in defective mitochondrial respiration, the levels of ATP, ADP, AMP, and energy charge (EC) was examined. Basal EC ( $[\text{ATP} + \text{half-ADP}]/[\text{ATP} + \text{ADP} + \text{AMP}]$ ), a measure of the overall energy status of the cell, was comparable in both autophagy-competent and autophagy-defective cells with and without Ras. Ras expression resulted in a drop in EC in *atg5<sup>+/+</sup>* cells upon starvation, which was decreased further by autophagy deficiency (Fig. 5F). Decreased EC in Ras-expressing, autophagy-defective cells was accompanied by a decreased ATP/ADP ratio and increased AMP levels (Supplemental Fig. S6D). Although mitochondrial ROS production has been associated with Ras-driven tumorigenesis (Weinberg et al. 2010), these data regarding EC implicate the energy-generating function of mitochondria. Ras expression amplifies energy depletion in starvation, rendering cells autophagy-dependent to buffer this demand by preservation of mitochondrial function and possibly also by production of catabolically derived metabolic substrates. In autophagy-defective cells, this metabolic insufficiency in starvation produces an acute energy crisis, leading to cell death.

## Discussion

Autophagy deficiency in mice produces tissues with swollen mitochondria and reduced respiration associated with ATP depletion, but also failure of protein and lipid homeostasis, and it is not often clear which contributes to disease manifestation (Kuma et al. 2004; Komatsu et al. 2005, 2006, 2007; Hara et al. 2006; Mathew et al. 2009; Wu et al. 2009). In post-mitotic tissues, the accumulation of autophagy protein substrates may be particularly toxic, resulting in tissue damage and disease. In contrast, tumors can lessen damaged protein accumulation through cell division, whereas damaged mitochondria may be more deleterious due to proliferation in a stressed microenvironment. Importantly, functional mitochondria are required for viability of Ras-transformed cells in starvation (Fig. 5C) and *in vivo* (Weinberg et al. 2010), suggesting that mitochondrial quality control by mitophagy is critical for maintaining oxidative metabolism and energy homeostasis when nutrients are limiting. Thus, autophagy suppresses cancer initiation while enabling growth of aggressive cancers. In the former, autophagy prevents tissue damage that can promote cancer initiation and progression of early stage cancers. In the latter, autophagy maintains mitochondrial metabolic function important for growth of aggressive cancers, creating “autophagy addiction.”

Tumors have different levels of mitochondrial bioenergetic function (Wu et al. 2007), attributable to oncogenic mutations and activation of signaling pathways that control metabolism (Vander Heiden et al. 2009) or mutations in

TCA cycle enzymes (Gottlieb and Tomlinson 2005) that promote aerobic glycolysis (Warburg effect) (Warburg 1956). As some oncogenic events suppress autophagy (White and DiPaola 2009), direct mitochondrial dysfunction derived from substrate limitation and defective mitophagy may also contribute to the Warburg effect. In the former, genetic reprogramming of metabolic pathways by mutation promotes aerobic glycolysis necessary for generation of anabolic precursors for biosynthetic pathways required for generation of new cells (Vander Heiden et al. 2009). In the latter, failure of mitochondrial quality control may prevent tumor cells from relying on oxidative metabolism to maintain cellular bioenergetics. By necessity, this may increase or select for reliance on glycolysis to support metabolism as Warburg (1956) originally described.

Cancers (such as lung, pancreatic, and colon) with a high prevalence of activating mutations in Ras have the unfortunate distinction of a particularly poor prognosis. We found that many human cancer cell lines with activating mutations in Ras have high basal autophagy, and some depend on autophagy for normal growth (T24, H1299, and HCT116) (Fig. 4E). The variance in autophagy dependence among human cancer cell lines could be due to differing additional mutations. Another intriguing possibility is that autophagy dependency may be related to high Ras activity and flux through the Ras pathway that occurs in more aggressive cancers and that is mimicked in the iBMK cells transduced with Ras. These findings suggest that these cancers with high levels of mutant Ras are most likely to respond to inhibition of autophagy, mitophagy, or mitochondrial metabolism. Indeed, autophagy is elevated in pancreatic cancer cell lines and tumors that display sensitivity to autophagy inhibition (Yang et al. 2011), consistent with the autophagy addiction model. Agents such as hydroxychloroquine (HCQ) that interfere with lysosome function at the terminal step of autophagic degradation have entered the clinic to test if autophagy inhibition can improve cancer treatment efficacy (White and DiPaola 2009). These data now inform and support a more individualized approach to assess for activating mutations in Ras in clinical trials of autophagy inhibitors. However, it is important to note that HCQ may not function equivalently to Atg5-shRNA- or Atg7-shRNA-mediated autophagy inhibition that block initiation of autophagosome formation. Development of specific autophagy inhibitors and determination of the optimal point in the autophagy pathway to compromise cancer cell survival is clearly warranted. Moreover, tumors with defective mitochondria may be particularly sensitive to agents that interfere with glucose utilization while being resistant to treatments that rely on toxic mitochondrial ROS production for cell killing.

## Materials and methods

### *Cell culture and reagents*

Baby mice iBMK cells were cultured in DMEM (GIBCO/Invitrogen) containing 10% fetal bovine serum (FBS) and 1% Pen-Strep at 38.5°C with 8.5% CO<sub>2</sub>. For human cancer cell lines, H460 and



PC-3 cells were cultured in RPM1640 with 10% FBS and 1% Pen-Strep; T24 and H1299 cells were grown in 10% DMEM with 10% FBS and 1% Pen-Strep; HCT116 cells were cultured in McCoy's 5A medium containing 10% FBS and 1% Pen-Strep; and PANC-1 cells were cultured in DMEM with 10% FBS, 1% sodium pyruvate, and 1% Pen-Strep. All human cancer cells were cultured at 37°C with 5% CO<sub>2</sub>. To assess the basal autophagy level, human cancer cells were cultured in nutrient-replete conditions and collected at 30% of confluence. For starvation conditions, cells growing in multiwell plates were washed twice with phosphate-buffered saline (PBS; GIBCO/Invitrogen) and placed in HBSS (GIBCO/Invitrogen). Cell viability was assessed by a trypan blue exclusion-based cell viability analyzer (Vi-CELL, Beckman Coulter, Inc.) and normalized to untreated cells at the time of initiation of starvation. Clonogenic survival assays were performed following normal or starvation conditions by restoring normal growth medium (DMEM + 10% FBS), and the recovered cells were then visualized by staining the plates with Giemsa (Sigma-Aldrich). N-Acetyl-L-cysteine (NAC), methyl-pyruvate, staurosporine, CCCP, bafilomycin A1, anti-mycin, and FCCP were purchased from Sigma-Aldrich.

#### Constructs and protein expression

pEGFP-p62 and pEGFP expression vectors were gifts from Dr. Terje Johansen, the pmCherry-Parkin expression vector was generously provided by Dr. Richard Youle, and the p-tFL-LC3 tandem-tagged LC3 expression vector was gift from Dr. Tamotsu Yoshimori. Flag-HA-tagged p62 was generated by fusion of human full-length p62 to the N-terminal epitope tag and cloned into pCDNA3.1 (+) (Invitrogen). To generate rabbit polyclonal anti-p62 antibodies, the full-length human p62 cDNA was cloned into pMal-C2x (NEB) at EcoRI and SalI enzyme-cutting sites. MBP-p62 fusion protein was expressed in BL21 (DE3) *Escherichia coli* by IPTG induction, affinity-purified using an amylose column, and then eluted with maltose. Rabbit polyclonal anti-p62 antibody was generated by Cocalico Biologicals, Inc., using the MBP-p62 fusion protein as an antigen.

#### Generation of cell lines

Immortal cell lines were generated as described previously (Degenhardt et al. 2002a,b). To obtain cells stably expressing H-ras<sup>V12</sup> or K-ras<sup>V12</sup>, *atg5*<sup>+/+</sup> and *atg5*<sup>-/-</sup> iBMK cell lines were cotransfected with the selection marker plasmid pcDNA3.1/Zeo (Invitrogen) and pCGN-HA-Hras<sup>V12</sup>, pCGN-HA-Kras<sup>V12</sup>, or control vector pCGN followed by zeocin (Invitrogen) selection; *atg7*<sup>+/+</sup>, *atg7*<sup>-/-</sup>, *beclin1*<sup>+/+</sup>, and *beclin1*<sup>+/-</sup> iBMK cell lines were transfected with pCGN-HA-Hras<sup>V12</sup> or control vector pCGN followed by hygromycin B (Sigma-Aldrich) selection; *p62*<sup>+/+</sup> and *p62*<sup>-/-</sup> iBMK cell lines were cotransfected by the selection marker plasmid pCMV-BSD (Invitrogen) with pCGN-HA-Hras<sup>V12</sup> or with control vector pCGN followed by blasticidin (GIBCO/Invitrogen) selection. p62 reconstituted cell lines were derived from *p62*<sup>-/-</sup>Hras cells engineered to stably express EGFP-p62 or Flag-HA-p62 by cotransfecting with pcDNA3.1/Zeo and pEGFP-p62 or pcDNA3.1(+)-Flag-HA-p62 followed by zeocin selection. *atg5*<sup>+/+</sup>Hras-mCherry-Parkin and *atg5*<sup>-/-</sup>Hras-mCherry-Parkin iBMK cell lines were derived from *atg5*<sup>+/+</sup>Hras or *atg5*<sup>-/-</sup>Hras cell lines transfected with pmCherry-Parkin and followed by geneticin (GIBCO/Invitrogen) selection. *atg5*<sup>+/+</sup>Hras-GFP-RFP-LC3 and *atg5*<sup>-/-</sup>Hras-GFP-RFP-LC3 cell lines were derived from *atg5*<sup>+/+</sup>Hras or *atg5*<sup>-/-</sup>Hras cells by transfecting with p-tFL-LC3 and followed by geneticin selection. pLKO.1-derived vectors with shRNAs targeting human *atg5* or *atg7* were purchased from Sigma-Aldrich (TRCN0000151963, TRCN0000330394

TRCN0000007584, and TRCN0000007587). Virus was produced using a second-generation packaging system in 293T cells as described (Root et al. 2006). Cells were selected in the presence of puromycin for 72 h prior to collection for analysis or experimental usage.

#### Antibodies

The following antibodies were used for Western blotting, immunohistochemistry, and immunofluorescence: p62 (antisera raised against MBP full-length human p62 described above or that purchased from Enzo Life Sciences); Beclin1 (H-300), and Tom20 (FL-145) (Santa Cruz Biotechnology, Inc.); ATG5-ATG12 (Cosmo Bio Co); HA (12CA5) (Roche Applied Science);  $\beta$ -actin and Ras (Sigma-Aldrich); LC3 and Ub (Ubi-1) (Novus Biologicals); and active caspase-3 (Asp175), phospho-S6, S6, phospho-p42/44, and p42/44 (Cell Signaling Technology, Inc.). Western blotting, immunohistochemistry, and immunofluorescence procedures were performed as described previously (Degenhardt et al. 2002b; Nelson et al. 2004; Mathew et al. 2009).

#### Electron microscopy

Tumors from *atg5*<sup>-/-</sup>, *atg7*<sup>-/-</sup>, *beclin1*<sup>+/-</sup>, *p62*<sup>-/-</sup>, or wild-type control iBMK cells expressing H-ras<sup>V12</sup> or K-ras<sup>V12</sup> were excised at day 11 post-injection and fixed in 0.1 M cacodylate buffer with 2.5% glutaraldehyde, 4% paraformaldehyde, and 8  $\mu$ M CaCl<sub>2</sub> and analyzed by a JOEL 1200EX electron microscope as described previously (Degenhardt et al. 2006).

#### Autophagy and mitophagy assessment

For quantification of autophagy induction, cells were transiently transfected (Amaya, Lonza) with the p-tFL-LC3 reporter and allowed to recover overnight. Cells were treated with 1 nM bafilomycin A1 to facilitate visualization of autophagosomes and incubated with HBSS for the indicated times prior to fixation and mounting. Images were analyzed at 60 $\times$ . A minimum of 200 cells was scored for each condition in three replicate experiments. The percentage of cells expressing RFP-LC3 puncta is indicated. The percentage of cells with mCherry-Parkin translocation was quantified by determining the number of cells displaying punctate (rather than diffuse) fluorescence out of a population of 100 fluorescent cells replicated in three independent experiments.

#### Tumor growth assays

Tumor formation assays and in vivo LC3 translocation were performed as described previously (Degenhardt et al. 2002b; Nelson et al. 2004; Mathew et al. 2009). Briefly, three mice per cell line and two independently derived cell lines per genotype were used to assess tumor formation. Cells (10<sup>7</sup>) (10<sup>6</sup> in Fig. 3D; Supplemental Fig. S2F, right panel) were subcutaneously injected in nude mice and growth was monitored at the indicated time points. Statistical significance was calculated by *t*-test. Tumor formation assays were performed using Institutional Animal Care and Use Committee-approved protocols.

#### Histology

For paraffin sections, tumors were fixed overnight in 10% buffered formalin solution (Formaldehyde-Fresh, Fisher Scientific) and sectioned. For fluorescent localization of p-tFL-LC3 tandem-tagged LC3 in vivo, tumors were fixed overnight in 10% buffered formalin solution followed by dehydration—first in 15% for 6 h, and then in 30% sucrose solution overnight—and sectioned.

### OCR rate measurement

OCR rates were measured using Seahorse Biosciences extracellular flux analyzer (XF24) as described previously (Wu et al. 2007). Briefly, cells were seeded at  $2.3 \times 10^4$  cells per well ( $0.32 \text{ cm}^2$ ) in XF24 plates in 250  $\mu\text{L}$  of DMEM (10% FBS, 1% Pen-Strep) and incubated for 20–24 h at  $38.5^\circ\text{C}$  and 8.5%  $\text{CO}_2$  prior to XF assay. Basal OCR measurements were made in HBSS and DMEM without and with sodium pyruvate (Invitrogen). SRC (maximal respiratory capacity – basal respiration rate) and total reserve capacity (Choi et al. 2009; Dranka et al. 2010) were measured under these conditions by injecting the mitochondrial uncoupler FCCP (1.5  $\mu\text{M}$ ), and Complex III inhibitor anti-mycin (20  $\mu\text{M}$ ), respectively, from XF24 reagent ports as indicated. All measurements were normalized to OCR per million cells.

### Metabolomic analysis by LC-MS

Pool size measurements in major TCA cycle intermediates by LC-MS were performed as described previously (Munger et al. 2006). Briefly, cells were cultured in complete media (DMEM, 10% dialyzed FBS, 1% Pen-Strep) for 20–24 h, after which media was replaced with HBSS for the indicated time. Metabolism was quenched by removing the media and adding 4 mL of methanol:water (80:20) at  $-80^\circ\text{C}$ . Extracted metabolites were dried under nitrogen flow, reconstituted in 350  $\mu\text{L}$  of water, and measured by LC-MS. Major TCA metabolites were selected and cell number-normalized pool sizes were calculated as an average of three replicate measurements using MatLab. For ATP, ADP, and AMP measurements, individual pool sizes were normalized to cell number and to known amounts of uniformly  $^{15}\text{N}$ -labeled ATP (4.89 nmol/mL) and  $^{13}\text{C}$ -labeled ADP (2.27 nmol/mL), and AMP (0.35 nmol/mL) added to the extraction media. EC was calculated using the formula  $\text{EC} = (\text{ATP} + \text{half-ADP})/(\text{ATP} + \text{ADP} + \text{AMP})$ . Statistical significance was calculated by two-way ANOVA with Bonferroni post-test.

### Assessment of mitochondrial membrane potential, ROS levels, and Ras activity

Live cells were stained with 25 nM MitoTracker-Red CMXRos (Molecular Probes/Invitrogen) and 25 nM MitoTracker-Green FM (Molecular Probes/Invitrogen) fluorescence dyes for 30 min under growth conditions, washed with growth medium, and analyzed by flow cytometry (BD influx cell sorter, BD Biosciences). ROS levels were determined using 10  $\mu\text{M}$  2',7'-dichlorodihydrofluorescein diacetate (DCF-DA, Molecular Probes) as described previously (Mathew et al. 2009). The Ras activity assay was performed as the manufacturer recommended (Thermo Fisher Scientific, Inc.). Briefly, 80  $\mu\text{g}$  of GST-Raf1-Ras-binding domain (RBD) was incubated in 500 mg of cell lysate together with glutathione resin for 1 h at  $4^\circ\text{C}$ . After incubation, the protein beads were retrieved, washed, resolved on 12% SDS-PAGE, and Western-blotted with an anti-Ras mouse monoclonal antibody.

### Acknowledgments

We thank M. Komatsu for the *atg7<sup>-/-</sup>* mice, T. Ishii for the *p62<sup>-/-</sup>* mice, R. Youle for the pmCherry-Parkin, T. Yoshimori for the p-tFL-LC3, and T. Johansen for the p62 expression vectors. We also thank R. Patel for the EM, and A. Roberts and the CINJ Flow Cytometry and Tissue Analytical Services and DNA sequencing core facilities. This work was supported by grants from the NIH (R37 CA53370 and RO1 CA130893 to E.W.; RC1 CA147961 to E.W., H.A.C., and J.D.R.; and R00 CA133181 to V.K.), the New Jersey Commission on Cancer Research (09-1083-CCR-EO to

E.W., C.G., H.C., J.D.R., and R.S.D.), and the DOD (W81XWH06-1-0514 and W81XWH05 to E.W. and R.S.D.).

### References

- Choi SW, Gerencser AA, Nicholls DG. 2009. Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. *J Neurochem* **109**: 1179–1191.
- Degenhardt K, Chen G, Lindsten T, White E. 2002a. BAX and BAK mediate p53-independent suppression of tumorigenesis. *Cancer Cell* **2**: 193–203.
- Degenhardt K, Sundararajan R, Lindsten T, Thompson C, White E. 2002b. Bax and Bak independently promote cytochrome C release from mitochondria. *J Biol Chem* **277**: 14127–14134.
- Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, et al. 2006. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* **10**: 51–64.
- Dranka BP, Hill BG, Darley-Usmar VM. 2010. Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. *Free Radic Biol Med* **48**: 905–914.
- Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, Moscat J. 2008. The signaling adaptor p62 is an important NF- $\kappa$ B mediator in tumorigenesis. *Cancer Cell* **13**: 343–354.
- Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. 2010. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol* **12**: 119–131.
- Gottlieb E, Tomlinson IP. 2005. Mitochondrial tumour suppressors: a genetic and biochemical update. *Nat Rev Cancer* **5**: 857–866.
- Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, et al. 2006. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* **441**: 885–889.
- Kim JW, Dang CV. 2006. Cancer's molecular sweet tooth and the Warburg effect. *Cancer Res* **66**: 8927–8930.
- Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, et al. 2005. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. *J Cell Biol* **169**: 425–434.
- Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, et al. 2006. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* **441**: 880–884.
- Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, et al. 2007. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell* **131**: 1149–1163.
- Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhiisa T, Mizushima N. 2004. The role of autophagy during the early neonatal starvation period. *Nature* **432**: 1032–1036.
- Levine B, Kroemer G. 2008. Autophagy in the pathogenesis of disease. *Cell* **132**: 27–42.
- Mathew R, Karantza-Wadsworth V, White E. 2007a. Role of autophagy in cancer. *Nat Rev Cancer* **7**: 961–967.
- Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White E. 2007b. Autophagy suppresses tumor progression by limiting chromosomal instability. *Genes & Dev* **21**: 1367–1381.
- Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, et al. 2009. Autophagy

- suppresses tumorigenesis through elimination of p62. *Cell* **137**: 1062–1075.
- Munger J, Bajad SU, Collier HA, Shenk T, Rabinowitz JD. 2006. Dynamics of the cellular metabolome during human cytomegalovirus infection. *PLoS Pathog* **2**: e132. doi: 10.1371/journal.ppat.0020132.
- Narendra D, Tanaka A, Suen DF, Youle RJ. 2008. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J Cell Biol* **183**: 795–803.
- Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E. 2004. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. *Genes & Dev* **18**: 2095–2107.
- Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Overvatn A, Bjorkoy G, Johansen T. 2007. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J Biol Chem* **282**: 24131–24145.
- Rabinowitz JD, White E. 2010. Autophagy and metabolism. *Science* **330**: 1344–1348.
- Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. 2006. Genome-scale loss-of-function screening with a lentiviral RNAi library. *Nat Methods* **3**: 715–719.
- Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* **324**: 1029–1033.
- Warburg O. 1956. On respiratory impairment in cancer cells. *Science* **124**: 269–270.
- Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. 2010. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *Proc Natl Acad Sci* **107**: 8788–8793.
- White E, DiPaola RS. 2009. The double-edged sword of autophagy modulation in cancer. *Clin Cancer Res* **15**: 5308–5316.
- White E, Karp C, Strohecker AM, Guo Y, Mathew R. 2010. Role of autophagy in suppression of inflammation and cancer. *Curr Opin Cell Biol* **22**: 212–217.
- Wild P, Dikic I. 2010. Mitochondria get a Parkin' ticket. *Nat Cell Biol* **12**: 104–106.
- Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrell J, Teich J, et al. 2007. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. *Am J Physiol Cell Physiol* **292**: C125–C136. doi: 10.1152/ajpcell.00247.2006.
- Wu JJ, Quijano C, Chen E, Liu H, Cao L, Fergusson MM, Rovira II, Gutkind S, Daniels MP, Komatsu M, et al. 2009. Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. *Aging* **1**: 425–437.
- Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'Antonio G, et al. 2011. Pancreatic cancers require autophagy for tumor growth. *Genes Dev* (in press).